Find information on thousands of medical conditions and prescription drugs.

Fabry's disease

Fabry's disease (or Angiokeratoma corporis diffusum) is a lysosomal storage disease caused by deficient alpha galactosidase. more...

Home
Diseases
A
B
C
D
E
F
Fabry's disease
Facioscapulohumeral...
Factor V Leiden mutation
Factor VIII deficiency
Fallot tetralogy
Familial adenomatous...
Familial Mediterranean fever
Familial periodic paralysis
Familial polyposis
Fanconi syndrome
Fanconi's anemia
Farber's disease
Fascioliasis
Fatal familial insomnia
Fatty liver
Febrile seizure
Fibrodysplasia ossificans...
Fibromatosis
Fibrosarcoma
Fibrosis
Fibrous dysplasia
Filariasis
Fissured tongue
Fitz-Hugh-Curtis syndrome
Flesh eating bacteria
Fluorosis
Focal dystonia
Foix-Alajouanine syndrome
Follicular lymphoma
Fountain syndrome
Fragile X syndrome
Fraser syndrome
FRAXA syndrome
Friedreich's ataxia
Frontotemporal dementia
Fructose intolerance
Fructose-1,6-bisphosphatase...
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Symptoms

Some of the pathological symtoms includes skin lesions, febrile episodes, burning in extremities. Skin lesions are painless elevated papules that appear all over body. Ocular involvement may present and showing vortex keratopathy. Death in early adulthood usually due to renal failure because of proteinuria induced hypertension.

Treatment

Treatment of Fabry's disease until recently was just symptomatic. This is changing with the drug Agalsidase beta (Fabrazyme®). Problematic is that the cost of the drug (approximately $170,000 US a year/patient) remains a barrier to many patients in some countries.

Read more at Wikipedia.org


[List your site here Free!]


Therapy OK'd for Fabry's disease
From Oakland Tribune, 4/25/03 by Lauran Neergaard, Associated Press

WASHINGTON -- Federal health officials have approved the first- ever treatment for Fabry's disease, a rare, inherited disorder that often kills its sufferers -- mostly men -- around age 50.

The treatment, Genzyme Corp.'s Fabrazyme, replaces a fat- metabolizing enzyme that Fabry's patients lack. Without that enzyme, fats build to extremely high levels inside organs, causing heart attacks and kidney failure as well as debilitating pain.

The Food and Drug Administration approved Fabrazyme Thursday under two special programs. One allows the sale of treatments for life- threatening diseases before there's complete proof they work. The other gives seven years of marketing exclusivity to the first approved therapy for disorders so rare they're classified "orphan diseases." Fabry's disease (fa-BRAY) is thought to afflict 5,000 people worldwide.

Fabrazyme is a genetically engineered version of the missing enzyme alpha-galactosidase A. In one study of 58 patients, intravenous infusions every two weeks significantly cleared fat deposits from the kidney and certain other tissues in two-thirds of recipients.

"It is a definite improvement in quality of life," said Jaime Martinez, 42, of Scotch Plains, N.J., who is participating in another Fabrazyme study.

The drug hasn't reversed his kidney damage, but Martinez no longer requires narcotics for the once-excruciating pain in his hands and feet, and for the first time in years has enough energy to play with his children each afternoon.

The hope is that by regularly lowering fat deposits, organ failure will be delayed or prevented, said FDA Commissioner Mark McClellan.

Genzyme's study to prove if Fabrazyme has that ultimate benefit won't be finished until at least next January. Fabrazyme was deemed promising enough to begin selling now, as long as Genzyme quickly provides confirmatory data.

Genzyme will begin U.S. sales in a few weeks. A spokeswoman refused to reveal the price, but in Europe, Fabrazyme costs about $180,000 a year.

Genzyme won FDA approval over a rival, Transkaryotic Therapies' Replagal. McClellan wouldn't address that drug's future.

The question now is whether Genzyme can ever adequately prove Fabrazyme's benefit, as required by federal law. Its ongoing study compares the drug to a dummy infusion.

Many participants who don't want to risk getting a placebo probably will drop out of the study once insurance coverage kicks in, expected in a few months.

Genzyme promised FDA that it will make special efforts to retain enough participants for a valid study, through such steps as switching placebo patients to Fabrazyme as soon as they show any kidney deterioration.

But FDA also plans to allow some novel statistical analyses -- including comparing medical records of how patients fared before Fabrazyme ever was developed -- in assessing the drug's benefit.

It's a crucial test for the biotechnology industry: How well Genzyme works with FDA in analyzing Fabrazyme could determine how easy it will be for other rare-disease treatments to win accelerated approval.

"This is a very important treatment, potentially," McClellan said. But, "I want to be very clear about this: Effective studies after approval are essential."

Fabrazyme comes with some serious side effects, including painful infusion reactions and allergic reactions. FDA cautioned that health workers should carefully monitor patients during the every-other- week infusions.

c2003 ANG Newspapers. Cannot be used or repurposed without prior written permission.
Provided by ProQuest Information and Learning Company. All rights Reserved.

Return to Fabry's disease
Home Contact Resources Exchange Links ebay